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Abstract
Background: Common variants on human chromosome 8q24, rs1447295 (C/A) and rs6983267
(T/G), have been recently linked to the prevalence of prostate cancer in European and American
populations. Here, we evaluated whether the single-nucleotide polymorphisms rs1447295 and
rs6983267 were associated with the risk of sporadic prostate cancer as well as latent prostate
cancer in a native Japanese population.
Results: We analyzed genomic DNA samples from 391 sporadic prostate cancer patients, 323
controls who had died from causes unrelated to cancer and 112 Japanese men who were diagnosed
as having latent prostate cancer based on autopsy results. The polymorphisms were determined by
allelic discrimination using a fluorescent-based TaqMan assay. The A allele of rs1447295 was
significantly associated with the risk of sporadic prostate cancer (p = 0.04; age-adjusted OR, 1.34),
while the G allele of rs6983267 showed a trend towards being a high-risk allele (p = 0.06; age-
adjusted OR, 1.27). No significant difference between these two polymorphisms and the risk of
latent prostate cancer was observed in the present Japanese population.
Conclusion: Known variants on human chromosome 8q24 may be risk factors for sporadic
prostate cancer in native Japanese men.
Background
The incidence of prostate cancer is widely known to be
much lower in Asian men than in Western men [1].
Recently, genome-wide association studies have revealed
a close relation between variants on human chromosome
8q24 and the risk of prostate cancer [2-13]. In 2006,
Amundadottir et al. [2] first identified a region on chro-
mosome 8q24 that was possibly linked to prostate cancer
in Icelandic men. Subsequently, Freedman et al. [3] con-
firmed an association between rs1447295 and the risk of
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prostate cancer in another ethnic cohort study. In yet
another study, the prevalence of the rs1447295 polymor-
phism associated with prostate cancer was investigated in
a population of Indian-born Asian Indians who had emi-
grated from India and were living in the United States
[14]. In 2007, Haiman et al. [8] and Yeager et al. [9]
showed a strong association between rs6983267 and the
risk of prostate cancer. Their investigations included Afri-
can Americans, Latino Americans, European Americans,
Japanese Americans, native Hawaiians, Australians, Swed-
ish, Icelanders, and the British, but not native Japanese or
other East Asian men. Thus, we felt that it was important
to replicate the study in a population of native Japanese
subjects to better understand the disparities in prostate
cancer risk among different ethnicities.
The characteristics of germline genetic polymorphisms
among patients with latent prostate cancer diagnosed at
the time of autopsy (LPCa) remain unknown. Stamey et
al. first proposed the pathologic entity of clinically diag-
nosed latent prostate cancers, which are defined as clini-
cally insignificant cancers [15]. Strictly speaking,
'insignificant prostate cancer' is not the same as 'LPCa',
and a comparative genetic analysis of clinically diagnosed
sporadic prostate cancer (SPCa) and LPCa might be useful
for a better understanding of the nature of this disease.
From this viewpoint, we also included LPCa subjects in
the present study to examine the genetic differences
between SPCa and LPCa patients.
Results
The characteristics of the control, SPCa, and LPCa groups
are shown in Table 1. The age distributions of the control,
SPCa, and LPCa groups were significantly different (p <
0.01). The T-stage distributions in the SPCa and LPCa
groups were also significantly different (p < 0.01). The
Gleason score distributions in the SPCa and LPCa groups
were not significantly different (p = 0.49). Genotyping
assays were successfully performed in all the subjects.
Table 2 shows the distributions of the genotypes and alle-
les of the rs1447295 and rs6983267 polymorphisms. The
genotype distributions for each SNP were consistent with
Hardy-Weinberg equilibrium (HWE).
Compared with the major allele homozygous genotype as
a reference, both the CA genotype of rs1447295 (p = 0.02;
age-adjusted OR, 1.54; 95% CI, 1.08 – 2.21) and the GG
genotype of rs6983267 (p = 7.0 × 10-3; age-adjusted OR,
2.21; 95% CI, 1.24 – 4.03) were significantly associated
with the risk of SPCa. Moreover, the CA + AA genotypes of
rs1447295 was also significantly associated with the risk
of SPCa (p = 0.02; age-adjusted OR, 1.50; 95% CI, 1.07 –
2.11). In allele-wise analyses, the A allele of rs1447295
was significantly associated with the risk of prostate can-
cer (p = 0.04; age-adjusted OR, 1.34; 95% CI, 1.01 – 1.79),
while the G allele of rs6983267 showed a tendency
towards an increase in the risk of prostate cancer (P = 0.06;
age-adjusted OR, 1.27; 95% CI, 0.99 – 1.62). One hun-
dred and twelve patients among 1,179 autopsied men
were diagnosed as having LPCa (9.5%). No significant dif-
ferences were observed between the control and the LPCa
patients (Table 3).
After stratification according to the Gleason score, T-stage,
and serum prostate specific antigen (PSA) levels at the
time of diagnosis, the frequencies of the CA and CA+AA
genotypes of rs1447295 were observed significantly
higher in SPCa patients with a Gleason score ≤7, a T-stage
of T3 or T4, and a serum PSA level ≥20 ng/mL; meanwhile,
the frequency of the GG genotype of rs6983267 was
observed significantly higher in SPCa patients with a
Gleason score ≥8, a T-stage of T1 or T2, and a serum PSA
Table 1: Characteristics of control, SPCa, and LPCa
Control
(N = 323)
SPCa
(N = 391)
LPCa
(N = 112)
p value
Age
median 79 71 81
range 49 – 100 48 – 89 66 – 98 < 0.01
T-stage
T1 or T2 167 102
T3 or T4 224 5 < 0.01
unknown 0 5
Gleason score
≤7 241 (92)* 62
≥8 150 (34)* 45 0.49
unknown 0 5
*Numbers of patients with SPCa who were undergone radical prostatectomy are described in the parenthesis.
—, not applicable.BMC Genetics 2009, 10:37 http://www.biomedcentral.com/1471-2156/10/37
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level ≥20 ng/mL (Table 4). We also investigated a com-
bined model examining the joint effect of both rs1447295
and rs6983267 on the prostate cancer risk. Individuals
with SPCa who carried both the CA (rs1447295) and the
GG (rs6983267) genotypes had a significantly higher risk
of prostate cancer (p = 0.03; age-adjusted OR, 2.74; 95%
CI, 1.13 – 7.17) (Table 5).
Discussion
The present case-controlled study investigated the relation
between variants on human chromosome 8q24 and the
risk of sporadic and latent prostate cancer in native Japa-
nese men. We confirmed that the rs1447295 and
rs6983267 polymorphisms were significantly associated
with the risk of sporadic prostate cancer in native Japanese
men. Table 6 shows the results of allele-wise analyses for
prostate cancer susceptibility in multi-ethnic studies. The
frequencies of the risk alleles and the magnitudes of the
effects found in our study were very similar to those previ-
ously reported for Japanese Americans [3,8]. Neither
rs1447295 nor rs6983267 was associated with the risk of
prostate cancer in African Americans; however, positive
associations with other genetic markers on chromosome
8, such as DG8S737 [2,8], rs16901979 [7,11],
rs13254738, rs6983561, broad11934905, rs7000448 [8],
and rs7008482 [11], were also reported in these subjects.
Whether these markers might also be valid for native Jap-
anese men should be confirmed in future studies. In a
genome-wide association study in subjects of European
ancestry [9], the ORs of the CA and AA genotypes of
rs1447295 were 1.43 and 2.23, respectively. In our results,
patients with the CA genotype of rs1447295 were more
likely to have prostate cancer (p = 0.02; age-adjusted OR,
1.54; 95% CI, 1.08–2.21); however, the AA genotype was
not significantly associated with prostate cancer in the
present study (p = 0.50; age-adjusted OR, 1.50; 95% CI,
0.62–2.73). In addition, the CA+AA genotypes of
rs1447295 were observed more frequently in the SPCa
group (p = 0.02; age-adjusted OR, 1.50; 95% CI, 1.07–
2.11), similar to the results of a previous study conducted
in Australian men [4]. As for the rs6983267 polymor-
phism, we could not find any significant association
between the G allele and SPCa (p = 0.06; age-adjusted OR,
1.27, 95% CI: 0.99–1.62), although Haiman et al. [8]
reported a significant association between these two fac-
tors (OR, 1.22; 95%CI, 1.05–1.42) in a study sample of
1,450 Japanese-Americans (722 patients with SPCa and
728 controls). The disparity between the results of their
report and ours might have been caused by the different
sample sizes.
In 2008, Terada et al. [16] initially studied 507 patients
with prostate cancer and 511 controls to determine the
association between these common variants on chromo-
some 8q24 and the risk of prostate cancer in a native Jap-
anese population. For their Japanese subjects, the A allele
of rs1447295 was significantly associated with the risk of
prostate cancer, while the G allele of rs6983267 was asso-
ciated with the risk of prostatic enlargement rather than
prostate cancer. Their findings for rs6983267 differed
from the results reported by Haiman et al. regarding the
risk of prostate cancer in Japanese Americans [8]. Terada
et al. adopted healthy male volunteers or patients of
benign disease as control, while our controls were patho-
logically confirmed to be the cases which have not suf-
fered from any malignancy by autopsy. We could not read
from their report whether they had surveyed of controls
by a PSA test or physical examination to exclude prostate
cancer subjects. We worried that they had a potential
chance including prostate cancer subjects among controls
and patients with benign prostatic hyperplasia. We think
careful setting of controls is a critical issue that interferes
with the results. During the course of our experiment, we
also observed a relation between the aggressiveness of
SPCa and these two SNPs. Thus, we investigated possible
interactions between these two independent SNPs. Our
results revealed a significant OR only in patients carrying
both the CA genotype of rs1447295 and the GG genotype
of rs6983267. While this result differed from that reported
by Yeager et al. [9] in a European population, the magni-
tude of the effect in our study was higher (age-adjusted
Table 2: Genotypic and allelic frequencies of rs1447295 and 
rs6983267 polymorphisms
Genotype Control (%)
(N = 323)
SPCa (%)
(N = 391)
LPCa (%)
(N = 112)
rs1447295
CC 218 (67.5) 217 (55.5) 71 (63.4)
CA 89 (27.5) 149 (38.1) 34 (30.4)
AA 16 (5.0) 25 (6.4) 7 (6.2)
rs6983267
TT 147 (45.5) 151 (38.6) 48 (42.9)
TG 151 (46.8) 181 (46.3) 53 (47.3)
GG 25 (7.7) 59 (15.1) 11 (9.8)
Allele Control (%)
(2N = 646)
SPCa (%)
(2N = 782)
LPCa (%)
(2N = 224)
rs1447295
C 525 (81.3) 583 (74.6) 176 (78.6)
A 121 (18.7) 199 (25.4) 48 (21.4)
HWE
chi-square 2.91 0.01 1.09
p value 0.09 0.93 0.30
rs6983267
T 445 (68.9) 483 (61.8) 149 (66.5)
G 201 (31.1) 299 (38.2) 75 (33.5)
HWE
chi-square 2.65 0.16 0.44
p value 0.10 0.69 0.51
HWE, Hardy-Weinberg equilibrium.BMC Genetics 2009, 10:37 http://www.biomedcentral.com/1471-2156/10/37
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OR, 2.74; 95% CI, 1.13–7.17). The accumulation of sam-
ples in collaboration with various international centers
would be indispensable for the further study of such inter-
actions.
The functional features of these polymorphisms are still
unclear. The closest characterized gene is the proto-onco-
gene  c-MYC, located approximately 264 kb from
rs1447295 [2,6]. Sato et al. [17] demonstrated that
patients with additional increases in the c-MYC  copy
number relative to the chromosome 8 centromere showed
a more rapid disease progression and earlier death from
cancer. Thus, clarifying the relation between c-MYC
amplification and the risk alleles among the polymorphic
markers located in 8q24 is a crucial task.
To the best of our knowledge, no study to date has exam-
ined common variants on human chromosome 8 among
subjects with LPCa. Our results suggested that the
rs1447295 and rs6983267 polymorphisms were not asso-
ciated with the risk of LPCa in native Japanese men. The
frequencies of each genotype in these subjects and the
controls were quite similar. We believe that such genetic
research in subjects with LPCa may be useful for clarifying
the genetic characteristics of clinically insignificant pros-
tate cancer.
In Japan, the age-adjusted incidence rate of prostate can-
cer was determined to be 26.2 per 100,000 in 2001 [18],
while that in Japanese Americans living in California was
determined to be 103.7 per 100,000 (2000 to 2002) [1].
Denis et al. [19] suggested that low intakes of vitamin E,
selenium, lignans and isoflavonoids affected the tumori-
genesis risk of prostate cancer. Marks et al. [20] reported
that Japanese Americans had more body fat, higher serum
triglyceride levels, lower estradiol levels, and much lower
soy-metabolite levels than native Japanese. Additionally,
Bettuzzi et al. [21] and Kurahashi et al. [22] emphasized
the protective effects of green tea constituents against the
risk of prostate cancer. These findings suggest that we need
to consider genetic and environmental factors, as well as
nutrition, in our attempts to prevent prostate cancer.
This study had several limitations. First, our sample size
was relatively small, and this might have influenced the
robustness of the results. Further study using larger sam-
ples for both the case and control groups is necessary. Sec-
ondary, several pathologists at the affiliated hospitals had
participated in the diagnosis of prostate cancer. Therefore,
we cannot deny the inter-observer variability existed.
Moreover, the data of Gleason score was underestimated,
because two thirds of the pathological data from SPCa
patients were obtained by biopsy.
Little is known about why the prevalence of prostate can-
cer is much lower in Asian populations than in other eth-
nicities. Researchers from Asia need to collaborate in
addressing this issue.
Conclusion
The present study demonstrates that polymorphisms on
8q24 are associated with the occurrence of prostate cancer
Table 3: Genotypic and allelic analyses of prostate cancer susceptibility
Genotype Control vs. SPCa Control vs. LPCa
OR* 95% CI p value OR* 95% CI p value
rs1447295
CC 1.0 reference 1.0 reference
CA 1.54 1.08 – 2.21 0.02 1.22 0.75 – 1.98 0.42
AA 1.29 0.62 – 2.73 0.50 1.45 0.53 – 3.59 0.45
CA + AA 1.50 1.07 – 2.11 0.02 1.25 0.79 – 1.97 0.33
rs6983267
TT 1.0 reference 1.0 reference
TG 0.95 0.67 – 1.35 0.78 1.17 0.74 – 1.86 0.50
GG 2.21 1.24 – 4.03 7.0 × 10-3 1.40 0.62 – 3.03 0.40
TG + GG 1.12 0.80 – 1.57 0.50 1.21 0.78 – 1.88 0.41
Allele
OR* 95% CI p value OR* 95% CI p value
rs1447295
C 1.0 reference 1.0 reference
A 1.34 1.01 – 1.79 0.04 1.23 0.84 – 1.79 0.29
rs6983267
T 1.0 reference 1.0 reference
G 1.27 0.99 – 1.62 0.06 1.17 0.84 – 1.62 0.35
OR*, Age-adjusted odds ratio.BMC Genetics 2009, 10:37 http://www.biomedcentral.com/1471-2156/10/37
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Table 4: Prostate cancer susceptibility stratified by Gleason score, T-stage, and serum PSA levels at diagnosis (control vs. SPCa)
Genotype Gleason score ≤ 7
(N = 241)
Gleason score ≥ 8
(N = 150)
OR* 95% CI p value OR* 95% CI p value
rs1447295
CC 1.0 reference 1.0 reference
CA 1.62 1.08 – 2.42 0.02 1.48 0.94 – 2.34 0.09
AA 1.09 0.46 – 2.56 0.84 1.63 0.66 – 3.92 0.29
CA + AA 1.53 1.04 – 2.25 0.03 1.50 0.97 – 2.32 0.07
rs6983267
TT 1.0 reference 1.0 reference
TG 0.93 0.62 – 1.39 0.73 0.90 0.57 – 1.42 0.66
GG 1.84 0.96 – 3.55 0.07 2.41 1.20 – 4.86 0.01
TG + GG 1.05 0.72 – 1.55 0.79 1.10 0.72 – 1.69 0.67
Genotype T1 or T2
(N = 167)
T3 or T4
(N = 224)
OR* 95% CI p value OR* 95% CI p value
rs1447295
CC 1.0 reference 1.0 reference
CA 1.39 0.88 – 2.17 0.15 1.70 1.14 – 2.56 0.01
AA 1.34 0.53 – 3.29 0.53 1.28 0.55 – 2.95 0.57
CA + AA 1.38 0.90 – 2.11 0.14 1.64 1.11 – 2.41 0.01
rs6983267
TT 1.0 reference 1.0 reference
TG 0.96 0.61 – 1.51 0.87 0.91 0.61 – 1.36 0.65
GG 2.68 1.37 – 5.30 4.0 × 10-3 1.69 0.87 – 3.31 0.12
TG + GG 1.19 0.78 – 1.83 0.42 1.02 0.69 – 1.49 0.93
Genotype PSA < 20 ng/mL
(N = 208)
PSA ≥ 20 ng/mL
(N = 183)
OR* 95% CI p value OR* 95% CI p value
rs1447295
CC 1.0 reference 1.0 reference
CA 1.46 0.95 – 2.23 0.08 1.71 1.12 – 2.60 0.01
AA 0.97 0.37 – 2.44 0.95 1.69 0.74 – 3.83 0.21
CA + AA 1.38 0.92 – 2.08 0.12 1.70 1.14 – 2.54 9.0 × 10-3
rs6983267
TT 1.0 reference 1.0 reference
TG 0.96 0.63 – 1.47 0.86 0.92 0.60 – 1.40 0.69
GG 1.46 0.72 – 2.96 0.30 2.74 1.45 – 5.24 2.0 × 10-3
TG + GG 1.03 0.69 – 1.55 0.88 1.16 0.78 – 1.73 0.47
Genotype Nonaggressive
(N = 99)
Aggressivea
(N = 292)
OR* 95% CI p value OR* 95% CI p value
rs1447295
CC 1.0 reference 1.0 reference
CA 1.69 0.98 – 2.91 0.06 1.54 1.06 – 2.25 0.02
AA 1.39 0.44 – 3.99 0.56 1.28 0.59 – 2.81 0.53
CA + AA 1.64 0.97 – 2.75 0.06 1.50 1.05 – 2.15 0.03
rs6983267
TT 1.0 reference 1.0 reference
TG 0.99 0.58 – 1.71 0.97 0.93 0.64 – 1.36 0.72
GG 1.45 0.58 – 3.46 0.42 2.32 1.29 – 4.26 0.01
TG + GG 1.05 0.63 – 1.78 0.85 1.12 0.79 – 1.60 0.52
OR*, Age-adjusted odds ratio.
a Aggressive, Gleason score ≥ 8, and/or T-stage T3 or T4, and/or PSA ≥ 20 ng/mL.BMC Genetics 2009, 10:37 http://www.biomedcentral.com/1471-2156/10/37
Page 6 of 8
(page number not for citation purposes)
in the native Japanese population. Our results confirm
that these polymorphisms are closely related to the risk of
SPCa; however, we did not observe an association
between these polymorphisms and the risk of LPCa. One
limitation of our study was that the number of our sam-
ples was relatively small; consequently, studies with larger
populations and family-based analyses are needed in the
future.
Methods
Study design
A total of 391 Japanese patients with SPCa who were
treated at the Department of Urology at the University of
Tokyo Hospital or at our affiliated hospitals located in the
Kanto area of Japan between January 1999 and August
2007 were enrolled. One hundred twenty-six cases under-
went a radical prostatectomy and the remaining cases
were treated with androgen-deprivation therapy. Adeno-
carcinoma of the prostate was pathologically confirmed in
all the cases, and the Gleason score was also evaluated by
pathologists working at each hospital. The clinical T stage
of the patients with SPCa was evaluated based on a digital
rectal examination, transrectal ultrasonography, pelvic
computed tomography, and pathological findings accord-
ing to the 2002 TNM staging system for cancer [23]. The
serum PSA levels at diagnosis were also measured.
Patients with a family history of prostate cancer were care-
fully excluded from this study. The mean age of the SPCa
patients was 70.7 ± 8.0 years (median, 71 years; range, 48
to 89 years). Genomic DNA samples were extracted from
peripheral blood specimens of these patients. The study
was conducted with the approval of the Ethics Committee
of the University of Tokyo and the internal review board
of each of the affiliated hospitals. Written informed con-
sent was obtained from each patient prior to their enroll-
ment in the study. We also examined 323 residence-
matched Japanese men as a control group. The mean age
of the patients in the control group was 79.2 ± 9.2 years
(median, 79 years; range, 49 to 100 years). All the patients
in the control group had died at the Tokyo Metropolitan
Geriatric Hospital and were consecutively autopsied. All
the control patients were pathologically confirmed to not
have suffered from any malignancy [24]. Moreover, we
examined 112 Japanese men who were diagnosed as hav-
ing LPCa at the time of autopsy. The mean age of the LPCa
patients was 81.9 ± 7.6 years (median, 81 years; range, 66
to 98 years). These patients had been registered in the
database of Japanese single nucleotide polymorphisms
for geriatric research (JG-SNP) [25]. Genomic DNA sam-
ples from the controls and LPCa cases were extracted from
frozen kidney tissues. The T stage of the patients with
LPCa was evaluated based on pathological findings
according to the 2002 TNM staging system for cancer [23].
Written informed consent was obtained from the patients'
family members under the Act of Postmortem Examina-
tion. This study was also reviewed and approved by the
Ethics Committee of the Tokyo Metropolitan Geriatric
Hospital. Moreover, this study was carried out in compli-
ance with the Helsinki Declaration.
Genotyping assay
Genotyping of the rs1447295 and rs6983267 polymor-
phisms was conducted using a TaqMan assay with an ABI
PRISM 7000 or 7300 sequence detection system (Applied
Biosystems, Foster City, CA, USA) according to the manu-
facturer's instructions. We adjusted the concentration of
the DNA solution to 100 ng/mL before using it. The
sequences of the specific primers and TaqMan probes and
the conditions for quantitative real-time polymerase
chain reaction were obtained from the website of the
National Cancer Institute http://
snp500cancer.nci.nih.gov/snp.cfm.
Statistical analysis
All the statistical analyses were conducted using JMP soft-
ware, version 7.0 (SAS, Cary, NC, USA). The chi-square
test was used to examine Hardy-Weinberg equilibrium
(HWE) and to compare the distribution of the genotypes
and alleles among the control, SPCa and LPCa patients.
To estimate the odds ratios (ORs) and 95% confidence
intervals (CIs), logistic regression analyses were per-
formed using age as a covariate to statistically adjust for its
potential confounding effects. Additionally, we estimated
ORs and 95%CIs after stratification according to the
Gleason score, T-stage, and serum PSA levels at diagnosis,
as just as Terada et al. reported [16]. P values less than
0.05 were considered significant.
Abbreviations
LPCa: latent prostate cancer diagnosed at the time of
autopsy; SPCa: clinically diagnosed sporadic prostate can-
cer; HWE: Hardy-Weinberg equilibrium; PSA: prostate
specific antigen; OR: odds ratio; CI: confidence interval.
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Table 5: Combined analysis with two polymorphisms
rs6983267
TT TG GG
rs1447295 OR* 1.0 0.78 1.69
CC 95% CI reference 0.50 – 1.23 0.78 – 3.75
OR* 1.07 1.33 2.74
CA 95% CI 0.58 – 1.94 0.77 – 2.29 1.13 – 7.17
OR* 0.54 1.34
AA 95% CI 0.15 – 1.81 0.42 – 4.48
OR*, Age-adjusted odds ratio.
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Table 6: Allele-wise analyses for prostate cancer risk in the multiethnic studies
rs1447295
A allele frequency
Author (Year) N cases/N controls Study population Cases Controls OR 95% CI p value
Amundadottir, et al. (2006) 1291/997 Iceland 0.17 0.11 1.72 — 1.7 × 10-9
1435/779 Sweden 0.16 0.13 1.29 — 4.5 × 10-3
458/247 European Americans 0.13 0.08 1.66 — 6.7 × 10-3
246/352 African Americans 0.34 0.31 1.15 — 0.29
Freedman, et al. (2006) 70/68 Native Hawaiians 0.37 0.16 3.02 1.66 – 5.50 1.5 × 10-4
449/465 Japanese Americans 0.24 0.17 1.48 1.18 – 1.86 3.4 × 10-4
640/567 Latino Americans 0.14 0.10 1.48 1.14 – 1.91 1.4 × 10-3
455/447 European Americans 0.13 0.10 1.35 1.01 – 1.80 0.02
989/804 African Americans — — 1.05 0.95 – 1.16 0.15
Wang, et al. (2007) 491/545 Caucasians 0.12 0.10 1.16 0.85 – 1.58 0.25
435/545 Caucasians* 0.17 0.10 1.93 1.37 – 2.72 4.0 × 10-3
Gudmundsson, et al. (2007) 1453/3064 Iceland 0.17 0.10 1.71 1.49 – 1.95 1.6 × 10-14
385/892 Spain 0.10 0.07 1.44 1.07 – 1.94 1.7 × 10-2
367/1302 The Netherlands 0.14 0.11 1.39 1.09 – 1.78 9.0 × 10-3
373/372 African Americans 0.32 0.31 1.01 0.81 – 1.25 0.96
Haiman, et al. (2007) 1614/837 African Americans — — — — —
722/728 Japanese Americans — — — — —
111/112 Native Hawaiians — — — — —
637/633 Latino Americans — — — — —
1182/942 European Americans — — — — —
Robbins, et al. (2007) 490/567 African Americans 0.34 0.31 1.40 0.70 – 1.30 0.13
Present study (2009) 391/323 Native Japanese 0.25 0.19 1.34 1.01 – 1.79 0.04
rs6983267
G allele frequency
Author (Year) N cases/N controls Study population Cases Controls OR 95% CI p value
Amundadottir, et al. (2006) 1291/997 Iceland — — — — —
1435/779 Sweden — — — — —
458/247 European Americans — — — — —
246/352 African Americans — — — — —
Freedman, et al. (2006) 70/68 Native Hawaiians — — — — —
449/465 Japanese Americans — — — — —
640/567 Latino Americans — — — — —
455/447 European Americans — — — — —
989/804 African Americans — — — — —
Wang, et al. (2007) 491/545 Caucasians — — — — —
435/545 Caucasians* — — — — —
Gudmundsson, et al. (2007) 1453/3064 Iceland — — — — —
385/892 Spain — — — — —
367/1302 The Netherlands — — — — —
373/372 African Americans — — — — —
Haiman, et al. (2007) 1614/837 African Americans 0.90† 0.84 1.43 1.17 – 1.75 —
722/728 Japanese Americans 0.37† 0.32 1.22 1.05 – 1.42 —
111/112 Native Hawaiians 0.36† 0.28 1.29 0.88 – 1.89 —
637/633 Latino Americans 0.63† 0.62 1.05 0.89 – 1.24 —
1182/942 European Americans 0.54† 0.51 1.13 0.99 – 1.28 —
Robbins, et al. (2007) 490/567 African Americans 0.08 0.11 1.40 0.90 – 2.40 0.17
Present study (2009) 391/323 Native Japanese 0.38 0.31 1.27 0.99 – 1.62 0.06
—, not applicable.
*, Familial prostate cancer cases.
†: We calculated the G allele frequencies of rs6983267. Genotype data were obtained from the supplementary Table 3 (reference No. 8).BMC Genetics 2009, 10:37 http://www.biomedcentral.com/1471-2156/10/37
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